Litigation Details for Blue Cross And Blue Shield Association v. Jazz Pharmaceuticals PLC (N.D. Ill. 2020)

Blue Cross And Blue Shield Association v. Jazz Pharmaceuticals PLC (N.D. Ill. 2020)

Docket		Date Filed	2020-06-17
Court	District Court, N.D. Illinois	Date Terminated	2020-07-15
Cause	15:15 Antitrust Litigation	Assigned To	Joan B. Gottschall
Jury Demand	Plaintiff	Referred To
Parties	ROXANE LABORATORIES, INC.
Patents	10,213,400; 6,780,889; 7,262,219; 7,668,730; 7,765,106; 7,765,107; 7,851,506; 7,895,059; 8,263,650; 8,324,275; 8,457,988; 8,589,182; 8,772,306; 8,859,619; 8,952,062; 9,050,302; 9,486,426; 9,539,330
Attorneys	Daniel J. Kurowski
Firms	Hagens BErman Sobol Shapiro LLP
Link to Docket	External link to docket

Details for Blue Cross And Blue Shield Association v. Jazz Pharmaceuticals PLC (N.D. Ill. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-06-17				External link to document
2020-06-17	1	complaint	10,213,400 Jan. 12, 2018 Feb. 26, 2019 Mar. 15, 2033 The patents in the …’219 patent, the ’730 patent, the ’106 patent, and the ’107 patent. 129. On October 14, 2010… Simply owning a patent does not entitle the patent owner to exclude others. Patents are routinely invalidated… acquired patent is not patentably distinct from the invention claimed in an earlier patent (and no exception… and ’062 patents). 119. The patents in the ’431 family also include two patents that claim	External link to document

Blue Cross and Blue Shield Association v. Jazz Pharmaceuticals PLC, 1:20-cv-03543: Litigation Summary and Analysis

Last updated: August 27, 2026

Blue Cross and Blue Shield Association v. Jazz Pharmaceuticals PLC, No. 1:20-cv-03543, is a private antitrust action concerning Jazz’s commercial and regulatory conduct involving Xyrem, an oxybate product used to treat narcolepsy. The case was part of multidistrict litigation alleging that Jazz delayed or impeded generic competition through its patent settlements, Risk Evaluation and Mitigation Strategy controls, product-switching conduct involving Xywav, and related regulatory strategies.

The action was not a conventional patent-infringement case. Its commercial significance arose from the theory that Jazz used patents, FDA regulatory controls, and lifecycle-management tactics to preserve Xyrem revenue and delay lower-cost generic sodium oxybate.

What is Blue Cross and Blue Shield Association v. Jazz Pharmaceuticals?

The case was filed by Blue Cross and Blue Shield Association and related Blue Cross Blue Shield entities against Jazz Pharmaceuticals PLC and affiliated entities. The plaintiff is a third-party payor that alleged it paid supracompetitive prices for Xyrem because Jazz allegedly restricted or delayed generic competition.

Item	Detail
Case	Blue Cross and Blue Shield Association v. Jazz Pharmaceuticals PLC
Civil action number	1:20-cv-03543
Subject	Antitrust claims involving Xyrem and generic sodium oxybate
Plaintiff	Blue Cross and Blue Shield Association and affiliated payors
Defendants	Jazz Pharmaceuticals PLC and related Jazz entities
Product	Xyrem, oral sodium oxybate
Related product	Xywav, mixed-salts oxybate
Legal area	Sherman Act, state antitrust, and related economic claims
Procedural setting	Related to multidistrict Xyrem antitrust litigation
Core theory	Jazz allegedly delayed generic entry and used lifecycle-management measures to maintain Xyrem exclusivity

The complaint focused on alleged exclusionary conduct rather than asserting that Jazz’s patents were invalid or unenforceable in a direct patent action.

What antitrust conduct did Blue Cross Blue Shield allege against Jazz?

The alleged conduct centered on Jazz’s control of the Xyrem market and its interactions with generic-drug manufacturers, regulators, and prescribers.

Patent settlements and generic entry

Jazz faced challenges to patents covering Xyrem and its distribution system. Payor plaintiffs alleged that Jazz used patent litigation and settlement agreements to delay generic sodium oxybate entry beyond the date that would have resulted from ordinary patent adjudication.

The relevant antitrust theory was that patent settlements could become unlawful “reverse-payment” arrangements if Jazz provided value to generic manufacturers in exchange for delaying market entry. The legal analysis would depend on the terms of each agreement, the strength of the challenged patents, the value transferred, and the agreed generic-entry date. Under FTC v. Actavis, a large and unexplained reverse payment may support antitrust scrutiny even when the underlying patent litigation was genuine.

REMS and distribution restrictions

Xyrem was distributed through a restricted pharmacy and risk-management system because sodium oxybate has abuse, misuse, and central nervous system-depressant risks. Plaintiffs alleged that Jazz used the Xyrem REMS and related distribution controls to interfere with generic manufacturers’ ability to obtain samples, develop products, or satisfy FDA requirements.

A REMS-related antitrust claim requires more than proof that the branded manufacturer participated in a regulated program. The plaintiff must connect the conduct to exclusionary effects and show that the conduct was not justified by legitimate safety requirements. Jazz’s likely defense was that the restrictions reflected FDA safety requirements and were necessary for controlled distribution of sodium oxybate.

Product switching from Xyrem to Xywav

Xywav contains the same active oxybate therapeutic concept as Xyrem but has a lower sodium burden. Jazz launched Xywav as Xyrem patents and generic competition approached.

The payor theory was that Jazz promoted Xywav and shifted patients away from Xyrem before generic Xyrem launch. Plaintiffs could characterize the conduct as “product hopping” if Jazz allegedly withdrew or disadvantaged Xyrem without a clinically meaningful justification, thereby preventing generic substitution.

Jazz’s principal response would be that Xywav offered a clinically differentiated formulation, including reduced sodium exposure, and that physicians and patients retained discretion to use Xyrem or other oxybate products. Product-hopping claims turn heavily on the timing of the switch, the availability of the original product, the degree of product differentiation, and the practical effect on generic substitution.

Regulatory petitions and market exclusion

The broader Xyrem antitrust litigation also involved allegations that Jazz used FDA citizen petitions, regulatory communications, and related submissions to delay approval or market access for generic sodium oxybate.

A regulatory filing is not independently unlawful merely because it delays a competitor. Under Noerr-Pennington principles, the filing generally must be shown to be objectively baseless and intended to use governmental process as an anticompetitive weapon. Plaintiffs therefore faced a substantial pleading burden on any sham-petition theory.

Was the case transferred to Xyrem multidistrict litigation?

Yes. The action was associated with the multidistrict proceeding addressing antitrust claims concerning Xyrem and sodium oxybate. The Judicial Panel on Multidistrict Litigation centralized related actions to promote coordinated discovery and pretrial proceedings.

What was the purpose of the MDL?

The MDL structure allowed the court to coordinate common questions involving:

• Jazz’s Xyrem patent estate;
• generic manufacturers’ patent challenges;
• settlement agreements and generic-entry dates;
• the Xyrem REMS;
• distribution and sample-access restrictions;
• Xywav lifecycle management;
• FDA petitions and regulatory conduct;
• damages paid by insurers, patients, and other purchasers.

The Blue Cross case was therefore part of a broader commercial dispute rather than an isolated insurance-payment claim.

What was the procedural effect?

Centralization did not decide liability. It consolidated discovery, motion practice, and pretrial management. The court still had to address standing, antitrust injury, causation, market definition, pleading sufficiency, and damages methodology.

The relevant market was likely framed around branded and generic sodium oxybate products for narcolepsy, although Jazz could argue that the market should include alternative narcolepsy treatments and the later Xywav product.

What patents and exclusivity protected Xyrem?

Xyrem’s protection did not depend on a single patent. Jazz relied on a layered estate covering composition, formulation, dosing, distribution, and related product characteristics.

Xyrem patent categories

Protection category	Antitrust relevance
Sodium oxybate composition or formulation patents	Supported infringement claims against generic products
Dosing and administration patents	Could restrict generic labeling or induce method-of-use disputes
Low-sodium or mixed-salt formulations	Supported Xywav differentiation
Restricted-distribution patents	Relevant to REMS and pharmacy-network allegations
Method-of-use patents	Could create skinny-label or carve-out issues
FDA regulatory exclusivity	Affected timing of approval and market entry

The Orange Book status of individual patents and their expiration dates were central to the expected generic-entry timeline. The antitrust plaintiffs’ theory required a comparison between lawful patent protection and the additional delay allegedly caused by settlements, REMS conduct, or product switching.

The action did not itself invalidate Jazz patents. Patent validity and infringement questions were relevant only insofar as they affected the economic analysis of Jazz’s exclusionary conduct and settlement agreements.

When did generic sodium oxybate competition emerge?

Generic sodium oxybate competition developed after years of patent litigation and settlement activity. The commercial dispute focused on whether generic entry occurred at the earliest lawful date or was delayed by Jazz’s conduct.

FDA approval and commercial-launch timing had separate components:

1. FDA approval of a generic application;
2. resolution of patent certifications and litigation;
3. any agreed settlement date;
4. manufacturing and distribution readiness;
5. pharmacy and prescriber access;
6. payer substitution and reimbursement.

Generic entry would have reduced the price of sodium oxybate, but the effect depended on the number of approved suppliers, whether the products were therapeutically substitutable, and whether Jazz shifted patients to Xywav before Xyrem generic substitution became meaningful.

What claims were asserted against Jazz?

The case was principally an antitrust and payor damages action. The asserted theories were expected to include federal and state claims arising from alleged exclusion of generic competition.

Principal legal theories

Sherman Act Section 2

The Section 2 theory required proof that Jazz possessed monopoly power in a properly defined market and acquired or maintained that power through exclusionary conduct rather than competition on the merits.

Potentially relevant conduct included:

• patent settlement agreements;
• misuse of the Xyrem REMS;
• interference with generic development;
• product switching to Xywav;
• regulatory petitions;
• alleged suppression of generic market entry.

Sherman Act Section 1

Section 1 claims required an agreement that unreasonably restrained trade. The focus would include agreements between Jazz and generic manufacturers and whether those agreements allocated market entry or transferred value in exchange for delayed competition.

State antitrust and consumer-protection claims

State-law claims could expand the geographic and damages analysis. Blue Cross plans operate across multiple jurisdictions, creating potential questions involving choice of law, indirect purchases, pass-on defenses, and differences among state antitrust statutes.

Unjust enrichment and related claims

Payor plaintiffs often plead unjust enrichment as an alternative theory. The economic premise is that Jazz allegedly received excessive revenues or avoided price competition at the expense of insurers and other purchasers.

How strong was Blue Cross Blue Shield’s case?

The case presented potentially credible economic theories but significant litigation hurdles.

Strengths of the plaintiff position

The plaintiff’s strongest points were likely:

• Xyrem had unusually high revenue and limited therapeutic substitution;
• sodium oxybate was subject to a restrictive distribution system;
• generic entry was commercially important to payors;
• Jazz controlled key safety, distribution, and regulatory information;
• the timing of Xywav’s launch coincided with anticipated Xyrem generic competition;
• patent settlements could be scrutinized under Actavis if they included substantial value transfers.

The combination of patent rights, REMS controls, and product migration created a fact-intensive record that could support discovery into Jazz’s internal strategy and communications.

Weaknesses and defenses

Jazz had several substantial defenses:

• valid patents can lawfully exclude generic competition;
• FDA-approved safety controls are not inherently anticompetitive;
• Xywav had a clinical distinction based on lower sodium content;
• generic manufacturers independently agreed to settlement terms;
• regulatory petitions may be protected petitioning activity;
• the plaintiff needed to prove that Jazz’s conduct caused actual overpayment;
• alternative narcolepsy treatments could weaken the relevant-market definition;
• payor damages could be affected by rebates, formularies, substitution rates, and patient migration.

The case therefore depended on evidence showing that the challenged conduct, rather than lawful patent protection or product differentiation, caused the alleged delay and economic harm.

What litigation issues affected damages?

Blue Cross and Blue Shield had to establish antitrust injury and quantify overcharges. The relevant damages period would depend on when generic competition should have entered absent the alleged conduct.

Key damages variables included:

Damages issue	Relevance
But-for generic-entry date	Determines the alleged overcharge period
Generic price erosion	Measures expected price reduction
Number of generic suppliers	Affects competitive discounting
Xyrem-to-Xywav switching	Determines which purchases were affected
Rebates and discounts	Reduces gross overcharge calculations
Formulary restrictions	Affects substitution rates
Patient and payer mix	Changes net exposure
State-law limitations periods	Limits recoverable periods
Pass-on and indirect-purchaser issues	Affects standing and allocation

A damages model based solely on the difference between Xyrem’s list price and a generic price would be vulnerable. The more defensible model would account for net prices, rebates, market shares, generic penetration, and the proportion of patients who would have remained on Xyrem rather than moved to Xywav or another treatment.

Did the case create Paragraph IV or biosimilar risk?

Paragraph IV risk

The case involved small-molecule generic risk, not a biosimilar dispute. Paragraph IV certifications were relevant because generic applicants could challenge Orange Book-listed patents by asserting that the patents were invalid, unenforceable, or not infringed.

The antitrust case did not replace Paragraph IV litigation. Instead, it used the patent-challenge history and settlement terms as evidence relevant to alleged generic delay.

Biosimilar risk

There was no meaningful biosimilar risk because Xyrem and Xywav are small-molecule drug products, not biologics. The competitive threat came from ANDA-based generic sodium oxybate products.

What was the commercial exposure for Jazz?

Xyrem was one of Jazz’s major products, with substantial historical revenue and high net pricing. A successful payor action could have exposed Jazz to:

• treble damages under federal antitrust law;
• damages under state antitrust laws;
• restitution or unjust-enrichment remedies;
• attorneys’ fees and litigation costs;
• increased settlement pressure in related private actions;
• reputational and regulatory consequences;
• accelerated erosion of the oxybate franchise.

The largest commercial risk was not limited to damages in the Blue Cross action. A finding of liability could have affected other payor, consumer, and end-purchaser claims involving the same alleged generic-delay conduct.

What was the litigation status and settlement posture?

The action was connected to coordinated Xyrem antitrust proceedings, and its substantive significance must be assessed through the MDL record rather than through the original complaint alone.

The case should not be characterized as a patent judgment against Jazz. The key questions were whether:

1. Jazz unlawfully maintained monopoly power;
2. the patent settlements involved actionable reverse payments;
3. the REMS system was misused to obstruct generic development;
4. the Xywav transition constituted exclusionary product hopping;
5. the alleged conduct caused overcharges to Blue Cross plans; and
6. the claims survived pleading, standing, causation, and class-certification challenges.

Any settlement involving Jazz and private payors would need to be analyzed separately from FDA approval, patent expiration, and generic-launch events. A settlement would resolve economic claims without necessarily establishing that Jazz’s patents were invalid or that its regulatory conduct violated FDA requirements.

How does this case compare with a patent-infringement action?

Issue	Blue Cross v. Jazz	Paragraph IV patent case
Plaintiff	Payor	Brand or generic manufacturer
Primary law	Antitrust	Patent law and Hatch-Waxman
Core question	Did conduct unlawfully delay competition?	Is the patent valid, infringed, or enforceable?
Remedy	Damages, restitution, injunction	Injunction, declaration, patent damages
Market evidence	Central	Usually secondary
Generic-entry date	But-for damages issue	Direct patent-litigation issue
FDA conduct	May support exclusionary-conduct theory	Usually relevant to approval and labeling
Patent validity	Indirectly relevant	Directly adjudicated

The case illustrates why a pharmaceutical company can face significant antitrust exposure even when its underlying patents remain enforceable. Patent rights provide a legal exclusion, but conduct surrounding those rights can still be challenged under antitrust law.

Key Takeaways

• Blue Cross and Blue Shield Association v. Jazz Pharmaceuticals, No. 1:20-cv-03543, concerned alleged suppression of generic sodium oxybate competition.
• The case was part of broader Xyrem antitrust litigation involving Jazz’s patent settlements, REMS controls, regulatory conduct, and Xywav lifecycle strategy.
• The action was not a direct patent-infringement or patent-invalidity case.
• The central economic question was whether Jazz delayed generic entry beyond the date justified by lawful patent rights.
• The Xywav product transition was important because it could reduce the practical effect of generic Xyrem substitution.
• The plaintiff faced substantial proof requirements involving market definition, causation, antitrust injury, and net overcharge damages.
• Jazz’s principal defenses included valid patent exclusion, FDA-mandated safety controls, clinical differentiation of Xywav, and lack of causation.
• The case had broader exposure implications because a liability finding could affect related payor and purchaser claims.

FAQs

Did Blue Cross sue Jazz for violating Xyrem patents?

No. The action was an antitrust and economic damages case. Xyrem patents and Paragraph IV litigation were evidence relevant to the alleged generic delay, not the direct cause of action.

Was Xywav included in the Blue Cross antitrust theory?

Yes. The transition from Xyrem to Xywav was relevant to the product-hopping theory and to the question of whether patients would have used generic Xyrem if it had entered earlier.

Could Jazz’s FDA-approved REMS create antitrust liability?

FDA approval did not automatically immunize Jazz from antitrust scrutiny. Liability would require proof that Jazz used the REMS or related controls beyond legitimate safety purposes to obstruct generic development.

Why were patent settlements important to the case?

Patent settlements can establish a delayed generic-entry date and may include payments or other value transfers. Under FTC v. Actavis, those features can support antitrust claims even when the underlying patent dispute was genuine.

Did the litigation create biosimilar competition against Jazz?

No. Xyrem and Xywav are small-molecule oxybate products. The relevant competitive pathway was generic approval under the ANDA and Paragraph IV framework, not biosimilar approval under the Biologics Price Competition and Innovation Act.

References

1. Blue Cross and Blue Shield Association v. Jazz Pharmaceuticals PLC, No. 1:20-cv-03543, Complaint and docket materials.

2. In re Xyrem (Sodium Oxybate) Antitrust Litigation, Multidistrict Litigation No. 2924, U.S. District Court for the District of Massachusetts, docket materials.

3. Federal Trade Commission v. Actavis, Inc., 570 U.S. 136 (2013).

4. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.

5. U.S. Food and Drug Administration. (n.d.). Xyrem and Xywav prescribing information and safety information.